HK1037180A1 - N-(3-ethynylphenylamino)-6,7-bis(2-mithoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate. - Google Patents

N-(3-ethynylphenylamino)-6,7-bis(2-mithoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate.

Info

Publication number
HK1037180A1
HK1037180A1 HK01105821A HK01105821A HK1037180A1 HK 1037180 A1 HK1037180 A1 HK 1037180A1 HK 01105821 A HK01105821 A HK 01105821A HK 01105821 A HK01105821 A HK 01105821A HK 1037180 A1 HK1037180 A1 HK 1037180A1
Authority
HK
Hong Kong
Prior art keywords
mithoxyethoxy
ethynylphenylamino
monohydrate
bis
quinazolinamine mesylate
Prior art date
Application number
HK01105821A
Other languages
English (en)
Inventor
Douglas John Meldrum Allen
Timothy Norris
Jeffrey William Raggon
Dinos Paul Santafianos
Ravi Mysore Shanker
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of HK1037180A1 publication Critical patent/HK1037180A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK01105821A 1998-04-29 2001-08-17 N-(3-ethynylphenylamino)-6,7-bis(2-mithoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate. HK1037180A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8344198P 1998-04-29 1998-04-29
PCT/IB1999/000612 WO1999055683A1 (en) 1998-04-29 1999-04-08 N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate

Publications (1)

Publication Number Publication Date
HK1037180A1 true HK1037180A1 (en) 2002-02-01

Family

ID=22178359

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01105821A HK1037180A1 (en) 1998-04-29 2001-08-17 N-(3-ethynylphenylamino)-6,7-bis(2-mithoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate.

Country Status (42)

Country Link
EP (1) EP1076652B1 (zh)
JP (1) JP4652569B2 (zh)
KR (1) KR100668412B1 (zh)
CN (2) CN1298396A (zh)
AP (1) AP1252A (zh)
AR (1) AR018201A1 (zh)
AT (1) ATE295839T1 (zh)
AU (1) AU759691C (zh)
BR (1) BR9910025A (zh)
CA (1) CA2330447C (zh)
CO (1) CO5060467A1 (zh)
CZ (1) CZ298230B6 (zh)
DE (1) DE69925366T2 (zh)
DZ (1) DZ2777A1 (zh)
EA (1) EA002836B1 (zh)
EG (1) EG24000A (zh)
ES (1) ES2238825T3 (zh)
GT (1) GT199900063A (zh)
HK (1) HK1037180A1 (zh)
HN (1) HN1999000057A (zh)
HU (1) HU227569B1 (zh)
ID (1) ID27198A (zh)
IL (1) IL139172A0 (zh)
MA (1) MA26624A1 (zh)
ME (1) MEP42008A (zh)
MX (1) MXPA00010610A (zh)
MY (1) MY136033A (zh)
NO (1) NO317301B1 (zh)
NZ (1) NZ508154A (zh)
OA (1) OA11769A (zh)
PA (1) PA8471001A1 (zh)
PE (1) PE20000441A1 (zh)
PL (1) PL196940B1 (zh)
RS (1) RS50081B (zh)
SA (1) SA99200216B1 (zh)
TN (1) TNSN99079A1 (zh)
TR (1) TR200003166T2 (zh)
TW (1) TWI248437B (zh)
UA (1) UA60363C2 (zh)
UY (1) UY26099A1 (zh)
WO (1) WO1999055683A1 (zh)
ZA (1) ZA992972B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
YU13200A (sh) 1999-03-31 2002-10-18 Pfizer Products Inc. Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
AU2004291709C1 (en) 2003-05-30 2010-03-11 Astrazeneca Uk Limited Process
WO2004111055A1 (en) 2003-06-10 2004-12-23 F. Hoffmann-La Roche Ag 1.3.4-triaza-phenalene and 1,3,4,6-tetraazaphenalene derivatives
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
BRPI0510717B8 (pt) 2004-05-06 2021-05-25 Bioresponse Llc uso de 3,3' diindolilmetano (dim) ou 2-(indol-3-ilmetil)-3,3´-diindolilmetano (ltr)
WO2006083458A2 (en) 2004-12-30 2006-08-10 Bioresponse Llc Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions
CN101547910A (zh) 2006-07-28 2009-09-30 合成纤维有限公司 结晶埃罗替尼
BRPI0717753B1 (pt) 2006-10-27 2022-04-12 Bioresponse, Llc Uso de uma composição compreendendo 50-250 mg de um ou mais indóis relacionados com dim e um ou mais agentes anti-protozoários, e, composição
AU2008235274B2 (en) * 2007-04-04 2013-04-18 Cipla Limited Process for preparation of erlotinib and its pharmaceutically acceptable salts
EP2162444B1 (en) 2007-07-11 2014-06-04 Hetero Drugs Limited An improved process for the preparation of erlotinib hydrochloride
US20100136116A1 (en) 2007-08-17 2010-06-03 Hetero Drugs Limited Novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b
KR101132937B1 (ko) * 2008-10-01 2012-04-06 주식회사종근당 N-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
US8440823B2 (en) 2009-03-26 2013-05-14 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
DE202010006543U1 (de) 2010-05-07 2010-09-09 Ratiopharm Gmbh Erlotinibresinat
HU230483B1 (hu) 2011-10-10 2016-07-28 Egis Gyógyszergyár Nyrt. Erlotinib sók
US9593083B2 (en) 2012-09-04 2017-03-14 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
EP1110953B1 (en) * 1995-03-30 2009-10-28 Pfizer Products Inc. Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines

Also Published As

Publication number Publication date
IL139172A0 (en) 2001-11-25
EA200001112A1 (ru) 2001-04-23
DE69925366T2 (de) 2006-03-09
DZ2777A1 (fr) 2003-12-01
SA99200216B1 (ar) 2006-06-04
CN1298396A (zh) 2001-06-06
UY26099A1 (es) 2001-12-28
DE69925366D1 (de) 2005-06-23
BR9910025A (pt) 2000-12-26
OA11769A (en) 2005-07-25
NO20005453L (no) 2000-12-20
JP2002513009A (ja) 2002-05-08
CZ20003974A3 (en) 2001-05-16
CA2330447C (en) 2009-06-30
HU227569B1 (en) 2011-08-29
NO317301B1 (no) 2004-10-04
EP1076652B1 (en) 2005-05-18
PA8471001A1 (es) 2000-09-29
CN101219999A (zh) 2008-07-16
UA60363C2 (uk) 2003-10-15
KR20010078710A (ko) 2001-08-21
HUP0101818A3 (en) 2002-05-28
RS50081B (sr) 2009-01-22
CZ298230B6 (cs) 2007-08-01
AP1252A (en) 2004-02-25
ID27198A (id) 2001-03-08
AP9901523A0 (en) 1999-06-30
NO20005453D0 (no) 2000-10-27
MA26624A1 (fr) 2004-12-20
AR018201A1 (es) 2001-10-31
PL196940B1 (pl) 2008-02-29
CA2330447A1 (en) 1999-11-04
AU759691C (en) 2004-04-29
CO5060467A1 (es) 2001-07-30
ZA992972B (en) 2000-10-30
MY136033A (en) 2008-07-31
TR200003166T2 (tr) 2001-02-21
TNSN99079A1 (fr) 2005-11-10
KR100668412B1 (ko) 2007-01-12
HUP0101818A1 (hu) 2002-03-28
EP1076652A1 (en) 2001-02-21
JP4652569B2 (ja) 2011-03-16
EA002836B1 (ru) 2002-10-31
WO1999055683A1 (en) 1999-11-04
PL343766A1 (en) 2001-09-10
MXPA00010610A (es) 2002-07-02
NZ508154A (en) 2003-07-25
PE20000441A1 (es) 2000-05-23
ES2238825T3 (es) 2005-09-01
EG24000A (en) 2008-03-19
MEP42008A (en) 2011-02-10
AU759691B2 (en) 2003-04-17
HN1999000057A (es) 1999-09-29
AU2850999A (en) 1999-11-16
TWI248437B (en) 2006-02-01
ATE295839T1 (de) 2005-06-15
YU66100A (sh) 2003-07-07
GT199900063A (es) 2000-10-20

Similar Documents

Publication Publication Date Title
HK1037180A1 (en) N-(3-ethynylphenylamino)-6,7-bis(2-mithoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate.
MXPA03001928A (es) Derivados de quinolina y quinazolina.
HUP0100941A3 (en) Quinoline, quinazoline and pyrido-pyrimidine derivatives and pharmaceutical compositions thereof
HK1092804A1 (en) New quinazoline derivatives
ZA986905B (en) Substituted quinazoline derivatives.
HUP9904631A3 (en) Fine-grained caoutchouc-powders, procedure for making them and the use thereof
AU7860901A (en) Quinazoline derivatives
GC0000108A (en) 4-Amino substituted-2-substituted-1,2,3,4-tetrahy droquinolines.
HK1049839A1 (zh) 喹啉和喹唑啉衍生物以及含有它們的藥物
HUP0203430A3 (en) Quinazolinones and their use
DE69910314D1 (de) Gruppenantenne und Funkgerät
HUP0203425A3 (en) Quinazoline derivatives, process for their preparation and their use
EP1066039A4 (en) SUBSTITUTED QUINAZOLINE AND THEIR ANALOGS AND USES
MXPA02007232A (es) Derivados aminados de dihidro-1,3,5-triazina y sus ojos terapeuticos.
EP1210084A4 (en) PYRIDOMORPHINANS, THIENOMORPHINANS AND THEIR USE
HUP0600238A3 (en) Benzothiazole- and benzoxazole-4,7-dione derivatives and their use
ZA985326B (en) Aminospiropiperidine quinazoline derivatives
ZA200108419B (en) Neurotrophin potentiators.
FR2798017B1 (fr) Dephaseur, et demodulateur utilisant ce dephaseur
ZA200109864B (en) Quinazoline derivatives.
DE60005282D1 (de) Golfschlägerkopf, golfschläger und golfschlägerset
ZA200202930B (en) Methods and compositions utilizing quinazolinones.
GB0015376D0 (en) Quinazoline derivatives
GB0030989D0 (en) Quinazoline derivatives
ZA200204264B (en) "Tunnel kiln".

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130408